Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothOffering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.

            Contact the Supplier

            Lead Product(s): Olopatadine Hydrochloride

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 17, 2020

            Details:

            Dr. Reddy’s has launched of over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the storebrand equivalents of Pataday® Once Daily Relief and Pataday® Twice Daily Relief, in the U.S. market, as approved by the USFDA.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluocinolone Acetonide

            Therapeutic Area: Ophthalmology Product Name: Iluvien

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 18, 2021

            Details:

            ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cetirizine

            Therapeutic Area: Ophthalmology Product Name: Zerviate

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 15, 2021

            Details:

            Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Loteprednol Etabonate

            Therapeutic Area: Ophthalmology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 11, 2021

            Details:

            Loteprednol Etabonate Ophthalmic Gel, 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.

            Famar Health Care Services Madrid

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bimatoprost

            Therapeutic Area: Ophthalmology Product Name: Zimed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Medicom Healthcare

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition February 10, 2021

            Details:

            Under this agreement, Medicom has acquired the ownership of the BIMATOPROST 0.3 mg/mL, 3ml dossier which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Netarsudil Mesylate,Latanoprost

            Therapeutic Area: Ophthalmology Product Name: Roclanda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 11, 2021

            Details:

            European Commission has granted a marketing authorisation for Roclanda® 0.02%/0.005% for high intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil are insufficient for IOP reduction.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Fluocinolone Acetonide

            Therapeutic Area: Ophthalmology Product Name: Yutiq

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: OcuMension Therapeutics

            Deal Size: $15.7 million Upfront Cash: Undisclosed

            Deal Type: Financing January 03, 2021

            Details:

            This investment underscores eyepoints' continued strong partnership with Ocumension for YUTIQ and DEXYCU in Asia. The companies in collaboration, are conducting Phase 1 trial of EYP-1901 in wet age-related macular degeneration.